In the heart of Wall Street’s relentless rhythm, where financial behemoths reign supreme, a solitary speck of defiance emerges: Immuno Arbitrage Partners.
A fund that sees arbitrage not as a bridge between two shores of opportunity, but as a labyrinthine maze of investment possibilities – an inexhaustible playground for the agile and the intrepid. We navigate this labyrinth with singular focus: the pursuit of alpha at any cost, barring one glaring principle we blithely ignore – common sense.
Our team is a motley assembly of quants, bankers, and economists, bound together by an unshakable faith in their own invincibility. We thrive on risk, nurture it like a precious seedling, watch it grow into a towering, unpredictable oak – then, with a reckless glee, we chop it down to sell its timber for profit.
Our internal KPI is not the traditional ‘Return on Investment’ or even the more daring ‘Shark Attack Factor’, but rather the ‘Risk of Being Caught by Regulators’ – a metric that, while seemingly counterintuitive, we’ve found to be strangely rewarding.
We embrace improbable risks with the enthusiasm of a trapeze artist leaping blindly into the void. Yet, should the unthinkable occur and we find ourselves teetering on the precipice of financial ruin, we merely shrug at market chaos – for us, it’s just another day in paradise.
0 Comments